Critical appraisal:Grenabo Bergdahl A, Holmberg E, Moss S, Hugosson J 2013 4
From Cancer Guidelines Wiki
Risk of bias assessment: randomised controlled trial
Was the trial double-blinded?
- Outcomes not blinded, substantial side-effects, or not reported.
Was the treatment allocation schedule concealed?
- Adequately concealed (e.g. central randomisation, numbered or coded bottles, drugs prepared by pharmacy).
Were all randomised participants included in the analysis?
- No exclusions or survival analysis used with all subjects included (>95% follow-up for all groups).
The field below is not considered when calculating the risk of bias rating
Overall risk of bias
|High risk of bias||Additional comments: Please replace this text and include any additional comments in regards to your quality rating|
- Grenabo Bergdahl A, Holmberg E, Moss S, Hugosson J. Incidence of prostate cancer after termination of screening in a population-based randomised screening trial. Eur Urol 2013 Nov;64(5):703-9 Available from: http://www.ncbi.nlm.nih.gov/pubmed/23721957.
- Assigned to
- Topic area
- Guidelines:PSA Testing/PSA Protocol
- Clinical question
Section below only relevant for Cancer Council Project Officer